Implementation of the guideline’s recommendations will prevent iatrogenic visual loss. The new guideline also makes recommendations regarding the techniques and timing of baseline and follow-up screening tests for both hydroxychloroquine and chloroquine retinopathy. Foods to avoid while taking plaquenil Hydroxychloroquine 200 mg daily What can you expect when you stop taking plaquenil Plaquenil Guidelines Point Out New Risks, New Presentation Written By Jean Shaw, Senior Editor, interviewing Rebekah A. Braslow, MD, Sang Jin Kim, MD, and Michael F. Marmor, MD Add to My To-Do List To help preserve vision over the long term, know the recommendations. “Today it is recommended that every single person on Plaquenil get a visual field 10-2 test, plus one of the three other highly sensitive screening tests the FAF fundus autofluorescence imaging, the SD-OCT spectral domain optical coherence, or the multifocal electroretinogram mfERG,” Thomas says. Newer guidelines state that daily dose 5mg/kg of real weight/day can lead to toxicity. Retinal toxicity is irreversible and can progress after cessation of hydroxychloroquine, thus early screening is important to limit potential vision loss. Baseline screening and annual screening after five years is recommended. In general, hydroxychloroquine is a safe and cost-effective medication, particularly when compared to newer anti-inflammatory medicines which can more significant adverse effects on the body. Hydroxychloroquine is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin. Plaquenil eye screening guidelines Hydroxychloroquine And Chloroquine Screening 2016 AAO., Protecting your eyesight when taking Plaquenil Lupus. Mefloquine vs chloroquinePlaquenil associated hyperpigmentationPlaquenil pigmentationHydroxychloroquine side efectsVisual field loss in plaquenil retinopathy AAO Screening Guidelines for Plaquenil by S P Check out my recent review/summary of the American Academy of Ophthalmology’s statement on the Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy 2016 Revision from the Ophthalmology Journal 2016;186-1394. AAO Screening Guidelines for Plaquenil. Hydroxychloroquine Plaquenil Toxicity and Recommendations.. Hydroxychloroquine and Chloroquine Retinopathy.. Plaquenil Hydroxychloroquine Eye Screening Plaquenil, also known as hydroxychloroquine, is a disease-modifying anti-rheumatic drug DMARD used to reduce inflammation and decrease pain caused by certain forms of arthritis and autoimmune disorders, such as rheumatoid arthritis and lupus. Dec 04, 2014 Screening Guidelines. In 2011, revised guidelines for HCQ retinopathy screening were published by the American Academy of Ophthalmology AAO, with an emphasis on more sensitive diagnostic imaging techniques. The AAO recommends that all patient receive a baseline evaluation before initiating HCQ therapy. The changes are most often permanent, but in some cases, vision has improved. Most rheumatologists recommend patients undergo a baseline eye examination prior to starting Plaquenil and be re-examined in the future depending on their risk for developing the condition. Risk factors include advanced age and having pre-existing retinal disease.